Skip to content
Research Article Open access CC BY 3.0

Novel and Investigational Drugs in Depression

Desiree N. Shapiro, Stephen M. Stahl

International Neuropsychiatric Disease Journal · pp. 328–347 · Published 17 Jul 2014

10.9734/INDJ/2014/11590

Abstract

Major depressive disorder is a serious medical illness associated with significant burden. Our current treatments for depression are limited, which has motivated researchers to explore novel targets. This article will highlight new psychopharmacological agents and investigational directions which may show promise in achieving better outcomes and symptom relief for those suffering from depression. This review will address key categories of novel therapeutic targets for depression. The newer and investigational agents involving monoaminergic transmission will be discussed, followed by those with glutamatergic, opioid, anticholinergic, and miscellaneous mechanisms. As the field continues to learn more about the pathophysiology of depression, there will be an emergence of additional innovative targets and investigational mechanisms, along with an improvement in our treatment outcomes.  

Antidepressants novel investigational major depressive disorder

Cited by 1

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

1

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.